Huons Co., Ltd. (KOSDAQ:243070)

South Korea · Delayed Price · Currency is KRW

19,000

-390 (-2.01%)

Oct 8, 2026, 3:30 PM KST

Market Cap	221.38B -35.8%
Revenue (ttm)	607.75B +2.1%
Net Income	18.86B -46.1%
EPS	1,618.97 -44.3%
Shares Out	11.65M
PE Ratio	11.74
Forward PE	n/a
Dividend	920.00 (4.84%)
Ex-Dividend Date	Aug 28, 2026

Volume	29,589
Open	19,450
Previous Close	19,390
Day's Range	18,910 - 19,450
52-Week Range	18,800 - 41,500
Beta	0.22
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Huons

Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1965

Employees 1,149

Stock Exchange KOSDAQ

Ticker Symbol 243070

Full Company Profile

Financial Performance

In 2025, Huons's revenue was 620.77 billion, an increase of 5.17% compared to the previous year's 590.23 billion. Earnings were 42.66 billion, an increase of 44.84%.

Financial Statements